DelveInsight’s, “Atopic Dermatitis Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the Atopic Dermatitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Atopic Dermatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Atopic Dermatitis Pipeline Report
- DelveInsight’s Atopic Dermatitis pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Atopic Dermatitis treatment.
- The leading companies working in the Atopic Dermatitis Market include Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co., Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd., GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others
- Promising Atopic Dermatitis Pipeline Therapies in the various stages of development include Baricitinib, si-544, MEDI9929, Dupilumab, Midazolam, Omeprazole, and others.
- June 2023: selectION Therapeutics GmbH announced a study of Phase 1 Clinical Trials for si-544. This is a multi-center, Phase 1b, double-blind, placebo-controlled, SAD and MAD, first-in-human study in subjects with mild to severe AD receiving si-544. The study consists of 2 parts, an SAD and an MAD part. In both parts, subjects will be treated in cohorts and will be randomized within each cohort to treatment with si-544 or placebo. Initially, 2 sentinel subjects will be treated (randomized to placebo or si-544) in each cohort.
- July 2023: Eli Lilly and Company announced a study of Phase 3 Clinical Trials for Baricitinib. The purpose of this study is to evaluate the long-term safety and efficacy of baricitinib in participants with atopic dermatitis.
Request a sample and discover the recent advances in Atopic Dermatitis Treatment Drugs @ Atopic Dermatitis Infection Pipeline Report
The Atopic Dermatitis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Atopic Dermatitis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Atopic Dermatitis clinical trial landscape.
Atopic Dermatitis Overview
Atopic dermatitis (AD) also called eczema, is a chronic condition and the most common type of skin inflammation that usually starts in early childhood, but can occur at any age and can be recurrent or persistent throughout life. In the word ‘dermatitis,’ ‘derm’ means ‘skin’ and ‘itis’ means ‘inflammation.’
Find out more about Atopic Dermatitis Treatment Drugs @ Drugs for Atopic Dermatitis Treatment
Atopic Dermatitis Emerging Drugs Profile
- Tapinarof: Dermavant Sciences
- Etrasimod: Pfizer
- B244: AOBiome
- Lirentelimab: Allakos Inc.
- QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Atopic Dermatitis Pipeline Therapeutics Assessment
There are approx. 100+ key companies which are developing the therapies for Atopic Dermatitis. The Atopic Dermatitis companies which have their Atopic Dermatitis drug candidates in the most advanced stage, i.e. phase III include, Dermavant Sciences.
Learn more about the emerging Atopic Dermatitis Pipeline Therapies @ Atopic Dermatitis Clinical Trials Assessment
Scope of the Atopic Dermatitis Pipeline Report
- Coverage- Global
- Atopic Dermatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Atopic Dermatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Atopic Dermatitis Companies- Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co., Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd., GI Innovation, AnaptysBio, MC2 therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others
- Atopic Dermatitis Pipeline Therapies- Baricitinib, si-544, MEDI9929, Dupilumab, Midazolam, Omeprazole, and others
Dive deep into rich insights for new drugs for Atopic Dermatitis treatment, Visit @ Atopic Dermatitis Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Atopic Dermatitis: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Atopic Dermatitis– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Tapinarof: Dermavant Sciences
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- B244: AOBiome
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- EP262: Escient Pharmaceuticals
- Drug profiles in the detailed report…..
- Inactive Products
- Atopic Dermatitis Key Companies
- Atopic Dermatitis Key Products
- Atopic Dermatitis- Unmet Needs
- Atopic Dermatitis- Market Drivers and Barriers
- Atopic Dermatitis- Future Perspectives and Conclusion
- Atopic Dermatitis Analyst Views
- Atopic Dermatitis Key Companies
- Appendix
For further information on the Atopic Dermatitis pipeline therapeutics, reach out to Atopic Dermatitis Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services